治疗精神疾病药物知识产权分析

Intellectual Property Analysis of Antipsychotic Drug

摘要: 世界各国精神疾病患者数量逐年上升，覆盖地区逐年增多，中国是精神疾病发病重灾区。国际上非常重视精神疾病治疗药物的研究，目前临床使用广泛且疗效优良的原研治疗精神疾病药物几乎被大型跨国制药企业垄断。本研究以精神药物专利申请量为评价指标，分析中国在精神药物研发方面的创新性。结果提示：1) 国内精神药物研发相对滞后，中国的制药业与发达国家和地区相比存在较大差距，国内制药企业在精神药物研发方面进行完全自主开发新药，在今后相当长时间内仍有一定难度；2) 通过对跨国公司专利到期时间的分析，仿制药开发和生产是国内在精神药物研发方面的方向之一。为了填补精神疾病药物研发的空白，缩短与国际间差距，我国应加强精神药物的创新和仿制力度。

Abstract: Currently the number of mental illness increased in each countries and the coverage area has increased every year, where China is the hardest area. The international community attaches great importance to the study of antipsy-chotic drugs, which excellent drugs, which are widely used in clinical and showed efficacy, monopolize by large multi-national pharmaceutical companies. This study analyzed the innovativeness on antipsychotic drugs in China, with its patent application for evaluation index. The results indicated that: 1) The development of domestic antipsychotic drugs were relatively dropped behind, in which there was a considerable gap compared with the pharmaceutical industry in China and developed countries, and the domestic companies were still more difficult to complete self-development of new drugs for quite a long time; 2) Generics development and production were the direction of domestic antipsychotic drugs, by analyzing the multinational patent expires time. In order to fill our gaps in antipsychotic drugs market, we should strengthen efforts in antipsychotic drugs of innovation and imitation.